CCL Products (India) Limited (NSE:CCL)
India · Delayed Price · Currency is INR 862.50
-49.70 (-5.45%)
Aug 6, 2025, 3:30 PM IST
Blueprint Medicines Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Operating Revenue | 33,881 | 31,057 | 26,537 | 20,712 | 14,620 | 12,425 | Upgrade |
Other Revenue | 74.22 | 63.56 | 58.19 | 31.12 | 39.6 | 30.69 | Upgrade |
| 33,955 | 31,121 | 26,595 | 20,743 | 14,660 | 12,455 | Upgrade | |
Revenue Growth (YoY) | 22.17% | 17.02% | 28.21% | 41.50% | 17.70% | 9.09% | Upgrade |
Cost of Revenue | 21,352 | 19,030 | 16,065 | 11,696 | 7,426 | 6,126 | Upgrade |
Gross Profit | 12,603 | 12,091 | 10,530 | 9,047 | 7,234 | 6,329 | Upgrade |
Selling, General & Admin | 1,778 | 1,743 | 1,483 | 1,150 | 998.22 | 808.56 | Upgrade |
Other Operating Expenses | 5,114 | 4,935 | 4,707 | 4,001 | 2,956 | 2,563 | Upgrade |
Operating Expenses | 7,982 | 7,662 | 7,167 | 5,788 | 4,528 | 3,866 | Upgrade |
Operating Income | 4,621 | 4,429 | 3,363 | 3,259 | 2,706 | 2,463 | Upgrade |
Interest Expense | -1,208 | -1,086 | -750.37 | -312.63 | -134.39 | -159.16 | Upgrade |
Interest & Investment Income | 20.97 | 20.97 | 4.97 | 1.44 | 1.34 | 2.16 | Upgrade |
Currency Exchange Gain (Loss) | 201.26 | 201.26 | 171.66 | 133.51 | 69.74 | 52.13 | Upgrade |
Other Non Operating Income (Expenses) | -42.63 | -42.63 | -26.76 | -31.38 | -29.2 | -10.39 | Upgrade |
EBT Excluding Unusual Items | 3,593 | 3,523 | 2,762 | 3,050 | 2,613 | 2,348 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | - | -0.03 | - | - | Upgrade |
Pretax Income | 3,593 | 3,523 | 2,762 | 3,050 | 2,613 | 2,348 | Upgrade |
Income Tax Expense | 479.44 | 419.17 | 261.6 | 210.39 | 569.83 | 525.22 | Upgrade |
Net Income | 3,113 | 3,103 | 2,501 | 2,840 | 2,044 | 1,823 | Upgrade |
Net Income to Common | 3,113 | 3,103 | 2,501 | 2,840 | 2,044 | 1,823 | Upgrade |
Net Income Growth | 19.35% | 24.10% | -11.93% | 38.96% | 12.12% | 9.84% | Upgrade |
Shares Outstanding (Basic) | 133 | 133 | 133 | 133 | 133 | 133 | Upgrade |
Shares Outstanding (Diluted) | 133 | 133 | 133 | 133 | 133 | 133 | Upgrade |
Shares Change (YoY) | 0.02% | 0.10% | 0.20% | - | - | - | Upgrade |
EPS (Basic) | 23.39 | 23.31 | 18.80 | 21.35 | 15.36 | 13.70 | Upgrade |
EPS (Diluted) | 23.34 | 23.26 | 18.76 | 21.35 | 15.36 | 13.70 | Upgrade |
EPS Growth | 19.33% | 23.99% | -12.12% | 38.97% | 12.12% | 9.86% | Upgrade |
Free Cash Flow | - | -1,283 | -4,579 | -1,590 | -736.71 | 162.91 | Upgrade |
Free Cash Flow Per Share | - | -9.61 | -34.35 | -11.95 | -5.54 | 1.23 | Upgrade |
Dividend Per Share | - | 5.000 | 4.500 | 5.500 | 5.000 | 4.000 | Upgrade |
Dividend Growth | - | 11.11% | -18.18% | 10.00% | 25.00% | 14.29% | Upgrade |
Gross Margin | 37.12% | 38.85% | 39.59% | 43.62% | 49.35% | 50.81% | Upgrade |
Operating Margin | 13.61% | 14.23% | 12.65% | 15.71% | 18.46% | 19.78% | Upgrade |
Profit Margin | 9.17% | 9.97% | 9.40% | 13.69% | 13.94% | 14.63% | Upgrade |
Free Cash Flow Margin | - | -4.12% | -17.22% | -7.66% | -5.03% | 1.31% | Upgrade |
EBITDA | 5,595 | 5,399 | 4,320 | 3,886 | 3,278 | 2,957 | Upgrade |
EBITDA Margin | 16.48% | 17.35% | 16.24% | 18.74% | 22.36% | 23.74% | Upgrade |
D&A For EBITDA | 974.09 | 970.64 | 956.82 | 627.27 | 571.98 | 494.12 | Upgrade |
EBIT | 4,621 | 4,429 | 3,363 | 3,259 | 2,706 | 2,463 | Upgrade |
EBIT Margin | 13.61% | 14.23% | 12.65% | 15.71% | 18.46% | 19.78% | Upgrade |
Effective Tax Rate | 13.35% | 11.90% | 9.47% | 6.90% | 21.80% | 22.37% | Upgrade |
Revenue as Reported | 33,976 | 31,142 | 26,600 | 20,745 | 14,661 | 12,459 | Upgrade |
Updated Feb 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.